In this article, we will look at the 8 Best Healthcare AI Stocks to Buy According to Analysts.
Healthcare AI stocks are getting more attention as investors look for places where artificial intelligence can move beyond chatbots and productivity tools into real-world markets. Healthcare is one of those areas where AI can touch drug discovery, diagnostics, medical imaging, clinical trials, hospital workflows, robotic surgery, and patient engagement. Janus Henderson frames the opportunity clearly, saying “AI is proving to have numerous applications in healthcare, from early detection of cancer to faster development of novel medicines.” The firm adds that these tools are “helping improve patient outcomes and creating efficiencies in the healthcare system,” which is why the theme is starting to matter for investors.
Capital Group says artificial intelligence is being used to “manage large data sets, improve clinical trial design and streamline operations,” while noting that “its operational benefits are becoming clearer.” This means that some of the nearer-term investment cases may come from less flashy areas like trial design, workflow automation, and cost efficiency.
That is why healthcare AI stocks deserve a closer look, especially those where the technology is tied to actual products, better clinical workflows, stronger data advantages, or clearer operating leverage. With that in mind, let’s take a look at the 8 Best Healthcare AI Stocks to Buy According to Analysts.
Our Methodology
We used the Finviz screener to identify healthcare AI stocks that offer upside of at least 25% based on analysts’ median price targets. We then limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
8. SOPHiA GENETICS SA (NASDAQ:SOPH)
On April 15, 2026, BTIG raised its price target on SOPHiA GENETICS SA (NASDAQ:SOPH) to $8 from $7 and maintained a Buy rating. The firm said management “signaled confidence across the business” following investor meetings with President and incoming CEO Ross Muken, CFO George Cardoza, and Head of Strategy Kellen Sanger.
In March, SOPHiA GENETICS SA (NASDAQ:SOPH) reported Q4 EPS of (28c) compared to (23c) a year earlier, while revenue rose to $21.7 million from $17.7 million. The company said performance was driven by 45% year-over-year growth in North America and 32% growth in the Asia Pacific. CEO Jurgi Camblong said the company finished 2025 with strong momentum, with Q4 revenue up 22% and full-year revenue increasing 19%.
For 2026, SOPHiA GENETICS expects revenue of $92 million to $94 million, above consensus estimates of $76.47 million, representing growth of about 20% to 22% year over year. The company also expects adjusted EBITDA in the range of ($29 million) to ($32 million).
SOPHiA GENETICS SA (NASDAQ:SOPH) provides cloud-based software tools that help healthcare providers analyze complex clinical data and generate insights across multiple diagnostic platforms.
7. Certara, Inc. (NASDAQ:CERT)
On April 22, 2026, Certara, Inc. (NASDAQ:CERT) said it entered into a definitive agreement to sell its regulatory and medical writing business to Veristat for up to $135 million. The deal is expected to close in the second quarter of 2026, subject to customary conditions. The divested unit generated $50 million in revenue and $17 million in adjusted EBITDA in 2025 and includes about 220 employees. Certara said it plans to update its 2026 guidance after the transaction closes.
On April 13, 2026, KeyBanc analyst Scott Schoenhaus lowered his price target on Certara, Inc. (NASDAQ:CERT) to $8 from $10 while maintaining an Overweight rating. The firm said the near-term setup remains largely positive ahead of Q1 earnings, although it expects most companies to reaffirm full-year guidance given macro uncertainty. KeyBanc added that healthcare utilization trends remain solid, supporting software spending, even as pharma digital advertising conditions remain uneven.
In March, UBS lowered its price target on Certara, Inc. (NASDAQ:CERT) to $10 from $15 while maintaining a Buy rating. The firm said fourth-quarter results and 2026 guidance challenged the bullish thesis, citing a services miss and slower software bookings. Despite that, UBS said Certara remains “uniquely positioned” in model-informed drug development.
Certara, Inc. (NASDAQ:CERT) provides biosimulation software and services used in drug discovery, clinical development, regulatory submissions, and commercialization.
Hedge Fund Resource Center